The UC Berkeley-founded gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.

The Pfizer and Chiesi-backed gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.

Ant Financial and Nikkei will have the chance to exit Chinese media and startup services provider 36Kr, which has filed for a $100m initial public offering in the US.

Harvard's genomic editing technology spinout has filed to raise up to $100m, adding to some $225m of venture funding in under three years.

The GV-backed genomic editing technology developer has filed to raise up to $100m, adding to some $225m of venture funding in under three years.

SR One and M Ventures, which own more than a fifth of shares between them, are in line for exits as Progyny files for an initial public offering on the Nasdaq Global Market.

Comcast NBCUniversal and Grace Beauty scored exits as Peloton Interactive floated at the top of its range to raise $1.16bn, getting a further $100m in a private placement.

Aprea Therapeutics, a Karolinska Institute spinout, is set to raise as much as $92m from an offering that would bank Karolinska Development a return of up to $8m.

CyberAgent, Marui, Mercari and Money Forward are all in line for exits after e-commerce technology provider Base received approval for its initial public offering.

Frequency Therapeutics, a regenerative medicine developer advancing MIT and Harvard research, has set the range for an initial public offering that will raise $107m if it floats at the high end.